| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000030240 |
| Receipt No. | R000034540 |
| Scientific Title | Randomized phase 3 trial evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of rectal cancer. |
| Date of disclosure of the study information | 2018/04/01 |
| Last modified on | 2022/12/12 (Ver. 10) |
| Basic information | ||
| Public title | Randomized phase 3 trial evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of rectal cancer. | |
| Acronym | EssentiAL study | |
| Scientific Title | Randomized phase 3 trial evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of rectal cancer. | |
| Scientific Title:Acronym | EssentiAL study | |
| Region |
|
|
| Condition | |||
| Condition | Rectal cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim of this study is to clarify the usefulness of blood flow evaluation by near infrared imaging using indocyanine green (ICG) as prevention of anastomotic leak after rectal anterior resection for rectal cancer by randomized controlled trial. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Anastomotic leakage rate |
| Key secondary outcomes | Anastomotic leakage rate(Grade B+C)
Fluorescence time at the oral side anastomotic site Rate of the additional transection of the proximal colon toward the oral side Length of the additional transection of the proximal colon toward the oral side Rates of complications within 30 days after surgery Rates of complications during surgery Reoperation rate Postoperative hospital stay |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | YES |
| Dynamic allocation | |
| Institution consideration | Institution is considered as adjustment factor in dynamic allocation. |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Evaluation of blood flow by near infrared imaging using indocyanine green | |
| Interventions/Control_2 | control | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients who are histologically proven to be rectal cancer
2. The lower edge of the tumor is within 12 cm from the anal margin 3. Patients diagnosed with Stage 0-3 in preoperative diagnostic imaging 4. Patients who are scheduled for rectal resection with intestinal anastomosis (including ISR) 5. Patients with General State Performance Status (ECOG) 0 to 2 6. Patients whose age at registration is 20 years or older 7. Patients whose functions of the main organs are adequately maintained and judged to be safe for surgery by the doctor in charge of examination 1 White blood cell count> 3,000 / mm 3 2 platelet> 100,000 / mm 3 3 GOT <100 IU / L 4 GPT <100 IU / L 5 Total bilirubin <2.0 mg / dl 6 Cr <2.0 mg / dl 8. About participation in this study Patients who have obtained consent from a document stating signature and date by the applicant |
|||
| Key exclusion criteria | 1. Patients who are allergic to iodine or indocyanine green
2. Preoperative intestinal obstruction patients 3. Patients planning simultaneous resection of other organs due to double cancer 4. Patients scheduled to anastomosis at more than two sites due to multiple colon cancer 5. Patients with intraperitoneal infection (peritonitis or abdominal abscess) 6. Patients with serious complications (heart disease, lung disease, bleeding tendency, poorly controlled hypertension, diabetes etc.) 7. Pregnancy and patients with fear thereof 8. Other patients judged inappropriate by the examining physician |
|||
| Target sample size | 850 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Sapporo Medical University | ||||||
| Division name | Department of Surgery, Surgical Oncology and Science | ||||||
| Zip code | 060-8556 | ||||||
| Address | Nishi 17, Minami 1 jyo, Cyuou-ku, Sapporo | ||||||
| TEL | 0116112111 | ||||||
| itakemasa@sapmed.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yokohama City University Medical Center | ||||||
| Division name | Department of surgery | ||||||
| Zip code | 232-0024 | ||||||
| Address | Urafune-cho 4-57 Minami-ku Yokohama | ||||||
| TEL | 045-261-5656 | ||||||
| Homepage URL | |||||||
| jun0926@yokohama-cu.ac.jp | |||||||
| Sponsor | |
| Institute | Sapporo Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Stryker Japan K.K. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Yokohama City University Certified Review Board |
| Address | 5F, 1-1-1, Fukuura, Kanazawa-ku, Yokohama |
| Tel | 046-261-5656 |
| jun0926@yokohama-cu.ac.jp | |
| Secondary IDs | |
| Secondary IDs | YES |
| Study ID_1 | CRB3180007 |
| Org. issuing International ID_1 | Yokohama City University Certified Review Board |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000034540 |